Do‐Youn Oh
Impact in
- Oncology top 0.05%
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 211
- Pancreatic and Hepatic Oncology Research 59
- HER2/EGFR in Cancer Research 42
- Colorectal Cancer Treatments and Studies 31
- Cancer Immunotherapy and Biomarkers 19
- Peptidase Inhibition and Analysis 19
-
- Gastric Cancer Management and Outcomes 48
- Lung Cancer Treatments and Mutations 19
- Co-authors
- Yung‐Jue Bang (191 shared papers)Seock‐Ah Im (194 shared papers)Sae‐Won Han (132 shared papers)Tae‐You Kim (72 shared papers)Luca Gianni (4 shared papers)David W. Miles (2 shared papers)Veronique C Dieras (2 shared papers)Sunil Verma (1 shared paper)
- Journals
- Annals of Oncology (47 papers)Cancer Research and Treatment (38 papers)BMC Cancer (19 papers)Gastric Cancer (16 papers)Cancer Chemotherapy and Pharmacology (14 papers)
- Partner nations
- South KoreaUnited StatesEthiopia
In The Last Decade
Do‐Youn Oh
446 papers receiving 32.5k citations
Do‐Youn Oh's Hit Papers
Peers
Comparison fields: 5 of 163
- Oncology 16.3k
- Cancer Research 4.1k
- Pulmonary and Respiratory Medicine 7.3k
- Surgery 7.6k
- Gastroenterology 831
Countries citing papers authored by Do‐Youn Oh
This map shows the geographic impact of Do‐Youn Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Do‐Youn Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Do‐Youn Oh more than expected).
Fields of papers citing papers by Do‐Youn Oh
This network shows the impact of papers produced by Do‐Youn Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Do‐Youn Oh. The network helps show where Do‐Youn Oh may publish in the future.
Co-authors
The 25 scholars most cited alongside Do‐Youn Oh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 460 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 3075 |
| 2 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1862 |
| 3 | Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer Hit paper breakdown → | 2019 | 1752 |
| 4 | Observation of Electron-Antineutrino Disappearance at Daya Bay Hit paper breakdown → | 2012 | 1508 |
| 5 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study Hit paper breakdown → | 2020 | 1207 |
| 6 | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2015 | 991 |
| 7 | HER2-targeted therapies — a role beyond breast cancer Hit paper breakdown → | 2019 | 835 |
| 8 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 808 |
| 9 | Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer Hit paper breakdown → | 2022 | 762 |
| 10 | Biliary tract cancer Hit paper breakdown → | 2021 | 754 |
| 11 | Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib Hit paper breakdown → | 2005 | 685 |
| 12 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 668 |
| 13 | Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial Hit paper breakdown → | 2023 | 668 |
| 14 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 587 |
| 15 | Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Hit paper breakdown → | 2019 | 582 |
| 16 | Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer Hit paper breakdown → | 2018 | 556 |
| 17 | Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma Hit paper breakdown → | 2017 | 554 |
| 18 | Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma Hit paper breakdown → | 2023 | 396 |
| 19 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies Hit paper breakdown → | 2020 | 385 |
| 20 | Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma Hit paper breakdown → | 2020 | 370 |
About Do‐Youn Oh
Do‐Youn Oh is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Cancer Research and Gastroenterology, having authored 460 papers that have together received 33.2k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (85 papers), Pancreatic and Hepatic Oncology Research (59 papers), Gastric Cancer Management and Outcomes (48 papers), HER2/EGFR in Cancer Research (42 papers), Colorectal Cancer Treatments and Studies (31 papers), Cancer Immunotherapy and Biomarkers (19 papers), Lung Cancer Treatments and Mutations (19 papers) and Peptidase Inhibition and Analysis (19 papers). The work is most often cited by research in Oncology (16.3k citations), Cancer Research (4.1k citations), Pulmonary and Respiratory Medicine (7.3k citations), Surgery (7.6k citations) and Gastroenterology (831 citations). Do‐Youn Oh has collaborated with scholars based in South Korea, United States and Ethiopia. Frequent co-authors include Yung‐Jue Bang, Seock‐Ah Im, Sae‐Won Han, Tae‐You Kim, Luca Gianni, David W. Miles, Veronique C Dieras, Sunil Verma, José Baselga and Mark Daniel Pegram. Their work appears in journals such as Annals of Oncology, Cancer Research and Treatment, BMC Cancer, Gastric Cancer and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.